JIVI DIN 02481790
Status: Marketed
Holder: BAYER INC
Health Canada record
| Active ingredient(s) | ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED) 3000 UNIT |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | B02BD02 COAGULATION FACTOR VIII |
| Original market date | 27-Jan-2020 |
| Current status date | 27-Jan-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bayer Inc — licence 101029, currently licensed, last inspection rating C (2023-02-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02481766 | JIVI | BAYER INC | Powder For Solution | ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED) 500 UNIT | Marketed |
| 02481774 | JIVI | BAYER INC | Powder For Solution | ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED) 1000 UNIT | Marketed |
| 02481782 | JIVI | BAYER INC | Powder For Solution | ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED) 2000 UNIT | Marketed |
| 02481758 | JIVI | BAYER INC | Powder For Solution | ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED) 250 UNIT | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 21437 | 2018-10-18 | New Drug Submission (NDS) |